Global Hemophilia Gene Therapy Competitive Landscape Professional Research Report 2024
Research Summary
Hemophilia gene therapy is an innovative medical approach aimed at treating hemophilia, a genetic disorder characterized by deficient or dysfunctional blood clotting proteins. Typically, hemophilia gene therapy involves introducing a functional copy of the clotting factor gene into the patient＇s cells, often using viral vectors as delivery vehicles. The goal is to enable the patient＇s cells to produce the missing clotting factor, thereby improving the blood clotting process. This approach holds the potential to provide a more sustained and long-term solution compared to traditional treatments, which often involve regular infusions of clotting factor concentrates. While hemophilia gene therapy is still an evolving field with ongoing research and clinical trials, early results have shown promise in increasing clotting factor levels and reducing the frequency of bleeding episodes in individuals with hemophilia.
According to DIResearch's in-depth investigation and research, the global Hemophilia Gene Therapy market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.
The major global manufacturers of Hemophilia Gene Therapy include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.
This report studies the market size, price trends and future development prospects of Hemophilia Gene Therapy. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Hemophilia Gene Therapy market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Hemophilia Gene Therapy market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Hemophilia Gene Therapy industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Hemophilia Gene Therapy Include:
Spark Therapeutics
Ultragenyx
Shire PLC
Sangamo Therapeutics
Bioverativ
BioMarin
uniQure
Freeline Therapeutics
Hemophilia Gene Therapy Product Segment Include:
Hemophilia A
Hemophilia B
Hemophilia Gene Therapy Product Application Include:
Female
Male
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Hemophilia Gene Therapy Industry PESTEL Analysis
Chapter 3: Global Hemophilia Gene Therapy Industry Porter’s Five Forces Analysis
Chapter 4: Global Hemophilia Gene Therapy Major Regional Market Size and Forecast Analysis
Chapter 5: Global Hemophilia Gene Therapy Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Hemophilia Gene Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Hemophilia Gene Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Hemophilia Gene Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Hemophilia Gene Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Hemophilia Gene Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Hemophilia Gene Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Hemophilia Gene Therapy Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources
- 1 Hemophilia Gene Therapy Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Hemophilia Gene Therapy Product by Type
- 1.2.1 Global Hemophilia Gene Therapy Market Size by Type, 2023 VS 2024 VS 2030
- 1.2.2 Hemophilia A
- 1.2.3 Hemophilia B
- 1.3 Hemophilia Gene Therapy Product by Application
- 1.3.1 Global Hemophilia Gene Therapy Market Size by Application, 2023 VS 2024 VS 2030
- 1.3.2 Female
- 1.3.3 Male
- 1.4 Global Hemophilia Gene Therapy Market Revenue Analysis (2019-2030)
- 1.5 Hemophilia Gene Therapy Market Development Status and Trends
- 1.5.1 Hemophilia Gene Therapy Industry Development Status Analysis
- 1.5.2 Hemophilia Gene Therapy Industry Development Trends Analysis
- 2 Hemophilia Gene Therapy Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Hemophilia Gene Therapy Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Hemophilia Gene Therapy Market Analysis by Regions
- 4.1 Hemophilia Gene Therapy Overall Market: 2023 VS 2024 VS 2030
- 4.2 Global Hemophilia Gene Therapy Revenue and Forecast Analysis (2019-2030)
- 4.2.1 Global Hemophilia Gene Therapy Revenue and Market Share by Region (2019-2024)
- 4.2.2 Global Hemophilia Gene Therapy Revenue Forecast by Region (2025-2030)
- 5 Global Hemophilia Gene Therapy Market Size by Type and Application
- 5.1 Global Hemophilia Gene Therapy Market Size by Type
- 5.2 Global Hemophilia Gene Therapy Market Size by Application
- 6 North America
- 6.1 North America Hemophilia Gene Therapy Market Size and Growth Rate Analysis (2019-2030)
- 6.2 North America Key Manufacturers Analysis
- 6.3 North America Hemophilia Gene Therapy Market Size by Type
- 6.4 North America Hemophilia Gene Therapy Market Size by Application
- 6.5 North America Hemophilia Gene Therapy Market Size by Country
- 6.5.1 US
- 6.5.2 Canada
- 7 Europe
- 7.1 Europe Hemophilia Gene Therapy Market Size and Growth Rate Analysis (2019-2030)
- 7.2 Europe Key Manufacturers Analysis
- 7.3 Europe Hemophilia Gene Therapy Market Size by Type
- 7.4 Europe Hemophilia Gene Therapy Market Size by Application
- 7.5 Europe Hemophilia Gene Therapy Market Size by Country
- 7.5.1 Germany
- 7.5.2 France
- 7.5.3 United Kingdom
- 7.5.4 Italy
- 7.5.5 Spain
- 7.5.6 Benelux
- 8 China
- 8.1 China Hemophilia Gene Therapy Market Size and Growth Rate Analysis (2019-2030)
- 8.2 China Key Manufacturers Analysis
- 8.3 China Hemophilia Gene Therapy Market Size by Type
- 8.4 China Hemophilia Gene Therapy Market Size by Application
- 9 APAC (excl. China)
- 9.1 APAC (excl. China) Hemophilia Gene Therapy Market Size and Growth Rate Analysis (2019-2030)
- 9.2 APAC (excl. China) Key Manufacturers Analysis
- 9.3 APAC (excl. China) Hemophilia Gene Therapy Market Size by Type
- 9.4 APAC (excl. China) Hemophilia Gene Therapy Market Size by Application
- 9.5 APAC (excl. China) Hemophilia Gene Therapy Market Size by Country
- 9.5.1 Japan
- 9.5.2 South Korea
- 9.5.3 India
- 9.5.4 Australia
- 9.5.5 Indonesia
- 9.5.6 Vietnam
- 9.5.7 Malaysia
- 9.5.8 Thailand
- 10 Latin America
- 10.1 Latin America Hemophilia Gene Therapy Market Size and Growth Rate Analysis (2019-2030)
- 10.2 Latin America Key Manufacturers Analysis
- 10.3 Latin America Hemophilia Gene Therapy Market Size by Type
- 10.4 Latin America Hemophilia Gene Therapy Market Size by Application
- 10.5 Latin America Hemophilia Gene Therapy Market Size by Country
- 10.5.1 Mecixo
- 10.5.2 Brazil
- 11 Middle East & Africa
- 11.1 Middle East & Africa Hemophilia Gene Therapy Market Size and Growth Rate Analysis (2019-2030)
- 11.2 Middle East & Africa Key Manufacturers Analysis
- 11.3 Middle East & Africa Hemophilia Gene Therapy Market Size by Type
- 11.4 Middle East & Africa Hemophilia Gene Therapy Market Size by Application
- 11.5 Middle East & Africa Hemophilia Gene Therapy Market Size by Country
- 11.5.1 Saudi Arabia
- 11.5.2 South Africa
- 12 Market Competition by Manufacturers
- 12.1 Global Hemophilia Gene Therapy Market Revenue by Key Manufacturers (2020-2024)
- 12.2 Hemophilia Gene Therapy Competitive Landscape Analysis and Market Dynamic
- 12.2.1 Hemophilia Gene Therapy Competitive Landscape Analysis
- 12.2.2 Global Key Manufacturers Headquarter and Key Area Sales
- 12.2.3 Market Dynamic
- 13 Key Companies Analysis
- 13.1 Spark Therapeutics
- 13.1.1 Spark Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.1.2 Spark Therapeutics Hemophilia Gene Therapy Product Portfolio
- 13.1.3 Spark Therapeutics Hemophilia Gene Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
- 13.2 Ultragenyx
- 13.2.1 Ultragenyx Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.2.2 Ultragenyx Hemophilia Gene Therapy Product Portfolio
- 13.2.3 Ultragenyx Hemophilia Gene Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
- 13.3 Shire PLC
- 13.3.1 Shire PLC Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.3.2 Shire PLC Hemophilia Gene Therapy Product Portfolio
- 13.3.3 Shire PLC Hemophilia Gene Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
- 13.4 Sangamo Therapeutics
- 13.4.1 Sangamo Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.4.2 Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio
- 13.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
- 13.5 Bioverativ
- 13.5.1 Bioverativ Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.5.2 Bioverativ Hemophilia Gene Therapy Product Portfolio
- 13.5.3 Bioverativ Hemophilia Gene Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
- 13.6 BioMarin
- 13.6.1 BioMarin Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.6.2 BioMarin Hemophilia Gene Therapy Product Portfolio
- 13.6.3 BioMarin Hemophilia Gene Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
- 13.7 uniQure
- 13.7.1 uniQure Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.7.2 uniQure Hemophilia Gene Therapy Product Portfolio
- 13.7.3 uniQure Hemophilia Gene Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
- 13.8 Freeline Therapeutics
- 13.8.1 Freeline Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.8.2 Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio
- 13.8.3 Freeline Therapeutics Hemophilia Gene Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
- 14 Industry Chain Analysis
- 14.1 Hemophilia Gene Therapy Industry Chain Analysis
- 14.2 Hemophilia Gene Therapy Industry Raw Material and Suppliers Analysis
- 14.2.1 Upstream Key Raw Material Supply Analysis
- 14.2.2 Raw Material Suppliers and Contact Information
- 14.3 Hemophilia Gene Therapy Typical Downstream Customers
- 14.4 Hemophilia Gene Therapy Sales Channel Analysis
- 15 Research Findings and Conclusion
- 16 Methodology and Data Source
- 16.1 Methodology/Research Approach
- 16.2 Research Scope
- 16.3 Benchmarks and Assumptions
- 16.4 Date Source
- 16.4.1 Primary Sources
- 16.4.2 Secondary Sources
- 16.5 Data Cross Validation
- 16.6 Disclaimer
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook